Onyx Pharmaceuticals Stock Rating Lowered by UBS AG (ONXX)
Onyx Pharmaceuticals (NASDAQ:ONXX) was downgraded by equities researchers at UBS AG from a “buy” rating to a “neutral” rating in a research report issued on Monday, TheFlyOnTheWall.com reports.
Onyx Pharmaceuticals (NASDAQ:ONXX) traded up 5.58% on Monday, hitting $123.49. The stock had a trading volume of 23,759,596 shares. Onyx Pharmaceuticals has a 52-week low of $68.12 and a 52-week high of $136.87. The stock has a 50-day moving average of $127.9 and a 200-day moving average of $99.06. The company’s market cap is $9.057 billion. Onyx Pharmaceuticals also was the target of some unusual options trading activity on Monday. Stock investors purchased 83,638 call options on the company. This is an increase of 332% compared to the average volume of 19,351 call options.
Onyx Pharmaceuticals (NASDAQ:ONXX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.42) by $0.02. The company had revenue of $153.00 million for the quarter, compared to the consensus estimate of $151.73 million. During the same quarter last year, the company posted ($0.68) earnings per share. Onyx Pharmaceuticals’s revenue was up 110.5% compared to the same quarter last year. On average, analysts predict that Onyx Pharmaceuticals will post $-1.56 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Onyx Pharmaceuticals in a research note to investors on Wednesday, August 21st. They now have a $120.00 price target on the stock. Separately, analysts at Maxim Group upgraded shares of Onyx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, August 20th. They now have a $130.00 price target on the stock. Finally, analysts at Barclays Capital raised their price target on shares of Onyx Pharmaceuticals from $123.00 to $130.00 in a research note to investors on Monday, August 12th.
Thirteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Onyx Pharmaceuticals presently has an average rating of “Hold” and an average target price of $123.42.
In other Onyx Pharmaceuticals news, EVP Helen Torley sold 9,311 shares of the stock on the open market in a transaction that occured on Monday, August 12th. The shares were sold at an average price of $126.89, for a total value of $1,181,472.79. Following the completion of the sale, the executive vice president now directly owns 46,585 shares of the company’s stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Onyx Pharmaceuticals, Inc (NASDAQ:ONXX) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.